WO2021171268A1 - Colorimetric detection system for rapid detection of infectious pulmonary diseases and a face mask with said colorimetric detection system - Google Patents

Colorimetric detection system for rapid detection of infectious pulmonary diseases and a face mask with said colorimetric detection system Download PDF

Info

Publication number
WO2021171268A1
WO2021171268A1 PCT/IB2021/051658 IB2021051658W WO2021171268A1 WO 2021171268 A1 WO2021171268 A1 WO 2021171268A1 IB 2021051658 W IB2021051658 W IB 2021051658W WO 2021171268 A1 WO2021171268 A1 WO 2021171268A1
Authority
WO
WIPO (PCT)
Prior art keywords
detection system
colorimetric
antibodies
aptamers
substrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2021/051658
Other languages
French (fr)
Inventor
Nuha Khalid ALAKHMINI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US17/802,408 priority Critical patent/US20230184757A1/en
Priority to EP21714665.3A priority patent/EP4111199B1/en
Priority to CN202180017082.9A priority patent/CN115210570A/en
Publication of WO2021171268A1 publication Critical patent/WO2021171268A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366Apparatus specially adapted for solid-phase testing
    • G01N33/54386Analytical elements
    • AHUMAN NECESSITIES
    • A41WEARING APPAREL
    • A41DOUTERWEAR; PROTECTIVE GARMENTS; ACCESSORIES
    • A41D13/00Professional, industrial or sporting protective garments, e.g. surgeons' gowns or garments protecting against blows or punches
    • A41D13/05Professional, industrial or sporting protective garments, e.g. surgeons' gowns or garments protecting against blows or punches protecting only a particular body part
    • A41D13/11Protective face masks, e.g. for surgical use, or for use in foul atmospheres
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/77Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
    • G01N21/78Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983Viruses
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6884Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/948Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486Metalloendopeptidases (3.4.24)
    • G01N2333/96491Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494Matrix metalloproteases, e. g. 3.4.24.7

Definitions

  • Colorimetric detection system for rapid detection of infectious pulmonary diseases and a face mask with said colorimetric detec tion system
  • the present invention relates to a colorimetric detection system for rapid detection of lung diseases, a colorimetric mask com prising said detection system, a method for producing a colori metric detection system, a method for producing a mask compris ing said detections system and the use of dyed microsphere for a colorimetric detection system.
  • Pulmonary infections are global health problems that can be spread anywhere. Spreading is in particular a problem in regions where many people live in cramped conditions. Likewise, seasonal holidays, such as carnival, or religious events, such as pil grimages, pose a challenge in preventing the spread of diseases. Viral and bacterial microbes play a major role in lung infec tions and different attempts have been undertaken to prevent spreading of these microbes. One way to prevent spreading would be a rapid detection method and isolation of infected persons. Another relatively efficient way of preventing spreading is the use of facial mask that cover mouth and nose. If a patient with a lung disease is coughing or sneezing into the mask, viruses and microbes such as bacteria are caught in the layers of the mask preventing their uptake by another person standing close to the patient.
  • Indicator sys tems are known that are based on color changes.
  • Schaude et al (Sensors 2017, 17, p. 1365) describes indicator cotton swabs for a faster and less expensive way to obtain information about a wound status.
  • the method is based on cotton swabs covalently functionalized with an indicator dye that changes color upon pH change visible to the naked eye.
  • the pH can be used to determine the efficiency of wound healing. In case the pH is not optimal for wound healing, a distinct treat ment to change the wound pH can be applied.
  • US 2019/0309357 A1 describes a detection system comprising a CRISPR system comprising an effector protein and one or more guide RNAs designed to bind to corresponding target molecules; an RNA masking construct and one or more detection aptamers cou pled with a detectable ligand.
  • Enzymes generate a detectable signal by releasing the detectable ligand form the molecule which can be detected by e.g. fluorescence.
  • the detection system can be prepared in freeze-dried format for convenient distribu tion and point-of-care.
  • a comparable system has been applied to face mask (according to www.businessinsider.com). However, the system still needs hours to obtain a diagnostic signal. Further, the detection system is based on PCR techniques, which is rather expensive. Fluorescence measurements are susceptible to inter ference leading to noise signals thus complicating the analysis.
  • a first aspect of the invention relates to a colorimetric detec tion system for rapid detection of lung diseases.
  • the detection system comprises antibodies and/or aptamers coupled to a sub strate for capturing a lung disease specific antigen.
  • the color imetric system further comprises dyed microspheres modified with the antibodies and/or aptamers for visually detecting the lung disease specific antigen.
  • Antibodies are large Y-shaped proteins used by the immune system to identify pathogenic bacteria or viruses.
  • the antibody recog nizes a unique molecule of the pathogen, called the antigen.
  • Aptamers are oligonucleotide or peptide molecules that bind to a specific target molecule. They can replace antibodies or used along antibodies for the same target.
  • the antibodies and/or aptamers coupled to the substrate are preferably coupled by covalent linkage and can be considered as capture antibodies and/or aptamers.
  • the modified dyed microspheres are preferably attached to the substrate by physical adsorption, thus being less strongly bound to the substrate than the capture antibodies/aptamers. However, they may also be bound by covalent linkage to the substrate.
  • the antibodies and/or aptamers attached to the dyed microsphere are preferably of the same kind as the capture antibodies/aptamer but show at least the same antigen specificity as the capture antibodies/aptamers .
  • the antibodies attached to the dyed microsphere may be referred to as detection antibodies and/or detection aptamers.
  • theyed can refer to attached color-causing ligands; color pigments, compounds or dyes enclosed in the mi crosphere or with dye coated microspheres. Suitable dyes are for example Polybead® dyed microsphere obtainable by Polysciences Inc. The Polybeads may have different colors such as blue, green, yellow, red, pink, orange.
  • the Polybead® microsphere can be Polybead® Polystyrene Microsphere, in the description also referred to as polystyrene microsphere or microsphere.
  • the dyed microspheres can be provided as a particle suspension with a concentration of 2.5 % solid per 100 mL.
  • the suspension may com prise particle diameters in the range of 0.05 mih to 90 mih. Parti cles with a diameter in the range of 0.5 to 90 mih account for 10 % or less of the solids in the suspension.
  • the microspheres can be functionalized with carboxyl-, hydroxyl-, or amine groups for coupling of the antibodies and aptamers.
  • the dyed microspheres used for coupling with the an tibodies and/or aptamers have a mean particle diameter of less than 6 mih, preferably even less than 3 mih, even more preferably less than 1 mih and most preferably less than 500 nm.
  • the indi vidual microspheres in the colorimetric detection system can have different nominal particle diameter, but preferably do not exceed 6 mih.
  • the sphericity of the dyed microspheres is prefera bly > 0.9, more preferably > 0.93, most preferably > 0.96. Individual microspheres with a diameter of less than 6 mih are not visible to the naked human eye and only allow detection upon agglutination thus providing a simple and effective detections system.
  • the substrate can comprise a protease, preferably a matrix-met alloproteinase.
  • the protease is coupled to the sub strate by functional groups such as carboxyl-, hydroxyl- or amine groups present on the substrate.
  • functional groups such as carboxyl-, hydroxyl- or amine groups present on the substrate.
  • Other proteases are also possible, for example PR3 or Elastase.
  • the protease has the advantage that a pathogen specific antigen coupled to the respective antibodies or aptamer are cleaved eas ier into smaller fragments (peptides and amino acids) thus al lowing more detection antibodies and/or aptamers to agglutinate to a larger network and thus allowing a faster detection.
  • the substrate can comprise discrete sections, each section being modified with antibodies and/or aptamers different from one of the other section for capturing a lung disease specific antigen different from the one captured in one of the other section.
  • a detection system that allows the detection of different pathogens simultaneously.
  • the detec tion system can comprise even more discrete sections, being only limited by the size of the substrate to allow visual detection.
  • one discrete section may comprise antibodies and/or aptamers specific for a pneumonia inducing bacteria while the other discrete section comprises antibodies and/or aptamers spe cific for a flue inducing antigen.
  • the dyed microsphere may have different colors in order to distinguish the different diseases.
  • the antibodies and/or aptamers can be influenza virus antibodies and/or aptamers; or a pneumonia or pneumonia-inducing antibodies and/or aptamers.
  • antigens that may be detectable by the colorimetric detection system are for example related to: viruses causing COVID-19, MERS, SARS, Flue A, Para Flue A Flue B, Para Flu B; bacteria such as Streptococcus, pneumonia, legionella, tubercu losis; or fungus such as actinomyces, aspergillus, Candida spp.
  • bacteria such as Streptococcus, pneumonia, legionella, tubercu losis
  • fungus such as actinomyces, aspergillus, Candida spp.
  • the list is not to be understood as exhaustive as basically every disease can be detected of which specific antibodies/ap- tamers are available.
  • the substrate is a solid support.
  • the substrate can be a hydrophilic material and/or oxidized cellulose.
  • the sub strate can be a cellulose based, paper-based or synthetic mate rial.
  • tissue paper, cotton or functionalized plas tic material can serve as substrate.
  • the substrate can basically have any shape. Due to its easy handling the strip format is preferred.
  • the substrate may have functional groups to allow coupling of the capture antibodies and/or aptamers, for example carboxyl-, hydroxyl- or amine groups, preferably by conventional carbodiimde coupling techniques.
  • the carbodiimide technique is in particular used to couple proteins and peptides via their n- terminus to carboxylic groups to form stable conjugates.
  • the hy- drophilicity allows the uptake of body liquids in the substrate.
  • any hydrophilic substrate that provides the above- mentioned conditions can be used. Further examples are silica or metal hydroxide such as aluminium hydroxide.
  • the working principle of the col orimetric system can be explained as follows: If a sample of salvia, sputum or nasal muscus of an infected person is applied to the substrate the substrate is humidified.
  • the pathogen spe cific antigen is caught by the capture antibodies or aptamers covalently attached to the substrate.
  • the protease allows cleav age of the antigen into smaller fragments for an efficient ag glutination of detection antibodies.
  • the humidified substrate allows movement of the detection antibodies.
  • the detection anti bodies or aptamers preferably attached to the substrate by physical adsorption, will attach to the pathogen/antivirus and may form agglutinated network.
  • the agglutination of the detec tion antibodies/aptamers causes an agglutination of the dyed mi crosphere resulting in the color appearance of the respective dyed microspheres to the naked eye and thus allowing visual de tection of the disease.
  • Single dyed microsphere may be undetect able by the naked eye as described further above.
  • the colorimetric detection system provides a simple, efficient and fast way of detecting lung infections.
  • the system can be easily prepared with low costs.
  • the color appears within the first 30 min after ap plying the sample to the substrate, preferably between 1 and 10 min after application and even more preferably between 1 to 5 min after application and most preferably between 1 and 3 min after application.
  • the detection system does response faster than other known method such as fluorescent measurements and is less prone to er rors. Further, no additional equipment is used for detection al lowing its application everywhere.
  • a second aspect of the invention relates to a colorimetric face mask for rapid detection of lung diseases.
  • the face mask is preferably designed to cover the mouth and the nose of a person.
  • the face mask comprises a first layer comprising the colorimet ric detection system as previously described.
  • the first layer can be made from the same mate rial as the substrate.
  • the substrate itself can serve as the first layer.
  • the first layer can also be made of material dif ferent from the substrate.
  • the first layer can com prise a hydrophobic material that prevents the adsorption of aqueous body liquids such as salvia.
  • the first layer can be pol ypropylene or a hydrophobised material.
  • the first layer can be impregnated material.
  • the substrate can be attached to the first layer, for example by sewing, ticking or gluing.
  • the face mask can comprise a second outer layer for protection against external pathogenic factors, preferably comprising a synthetic polymer such as polypropylene.
  • the outer layer can be obtained by polymeric fibres for exampling by spinning or weav ing.
  • the outer layer is made of a hydrophobic mate rial to avoid the uptake of pathogen-containing fluids such as aerosols, salvia or mucus of persons standing nearby.
  • the outer layer can comprise impregnated material. Most preferably, the outer layer is impermeable to microparticle but allows easy breathing of the user.
  • the impregnated material can be any textile or paper material, of natural or synthetic origin, that has been treated with res ins or other substances known in the art, or even has been guan idine-functionalized, in order to avoid water uptake and/or to obtain an antimicrobial effect.
  • the outer layer protects the user from being infected with a lung disease by others. At the same time is also prevents a false detection due to pathogens present in the environment instead of being present in the patient's body liquid. Further, it also avoids the visual detection by others which may lead to panic or the like.
  • pathogenic factors all disease-causing pathogens, mi crobes and small particles are meant, in particular viruses, bacteria, fungus, dust and smog.
  • the working principle of the face mask can be explained similar as done with regard to the colorimetric detection system with the difference that the pathogen specific antigen containing sample is provided by sneezing or coughing into the mask.
  • the coughing or snoozing brings the salvia, sputum or nasal muscus to the mask and humidifies the substrate.
  • the humidified sub strate allows movement of detection antibodies to the antigen and the agglutination to the network allowing.
  • the agglutination of the detection antibodies/aptamers causes an agglutination of the dyed microsphere resulting in the color appearance of the respective dyed microspheres to the naked eye and thus allowing visual detection of the disease.
  • Single dyed microsphere may be undetectable by the naked eye as described further above.
  • the colorimetric mask offers a cheap, fast and reliable method of detection a patient's or any other infected person's lung disease and at the same time prevents the spreading of the path ogens, thus lessen the risk of disease spreading.
  • the color can appear within the first 30 min after release of the pathogen by e.g. sneezing or coughing, preferably between 1 and 10 min after release and even more preferably between 1 to 5 min after release and most preferably between 1 and 3 min.
  • the first layer comprises the colorimetric detection system with two or more discrete sections for the detection of different pathogens as previously described.
  • one discrete section may comprise antibodies and/or aptamers spe cific for a pneumonia inducing bacteria while the other discrete section comprises antibodies and/or aptamers specific for a flue inducing antigen.
  • the dyed microsphere may have different colors in order to distinguish the different diseases.
  • Such a mask allows the detection of several lung diseases and thus no separate mask for each kind of infection has to be pro vided.
  • the colorimetric detection system can be located in the centre of the first layer, preferably in a circular arrangement. With “centre” is meant the middle of a plane forming cloth. Thus, the colorimetric detection system is closest to the mouth and nose, where the highest concentration on pathogen can be expected and thus leading to a fast detection. If more than one discrete sec tion is used, the detection system is preferably arranged in a circle and divided into pie-shaped sections. However, other shapes may also be possible as long as a contact between patho gen and detection system can be ensured.
  • the colorimetric mask can comprise a third inner layer for hid ing the result of the visually detected lung disease.
  • the third inner layer is preferably permeable to fluids and preferably comprises a cotton based material. Permeability can thus either be achieved by the material itself or by providing fluid pas sage, such as holes, in the third layer to allow contact of the pathogen containing body fluid with the detection system in the first layer. In principle, all material mentioned with regard to the first and second layer can be used for the third layer.
  • the third layer avoids the visual detection of the disease by the patient himself. Most preferred, the visual appearance of the colors can only be interpreted by medical staff and thus avoiding revelation to the patient or surrounding people which may cause panic or fear.
  • the mask may comprise fixation loops for fixing the mask to the head.
  • the loops can be handcrafted rubber strings with two metal copper rings inside, rubber bands or cords for closing at the back of the head. This way, the mask is holed in place and wear ing is comfortable. The mask can thus be worn for a couple of hours.
  • a third aspect of the invention refers to a method for producing a colorimetric system as previously described.
  • the method com prises the steps of
  • the substrate may be a hydrophilic material already containing the reactive sites or the substrate may have been modified in a previous step.
  • the substrate can originate from cellulose which has been oxidized.
  • the substrate can be oxidized cellulose.
  • the substrate can be any other hydrophilic material that provides reactive sites towards antibodies and/or aptamers.
  • the antibodies and/or aptamers may be coupled to the substrate via the reactive groups.
  • the reactive groups can be carboxyl-, hydroxyl-, amine- or sulfuric groups. Carboxyl groups are pre ferred. Coupling of the antibodies and aptamers can be conducted by carbodiimide crosslinking chemistry known in the art. In gen eral, any coupling method that allows the N- or C-terminus of the antibody/aptamer to be coupled to the substrate is possible.
  • Blocking of non-reactive sites is preferably obtained by using bovine serum albumin (BSA).
  • BSA bovine serum albumin
  • Attachment of the dyed microspheres modified with the antibodies and/or aptamers to the substrate is preferably obtained by phys ical adsorption.
  • the substrate can be immersed into a solution comprising the modified dyed microspheres. De tails to the microsphere have been previously provided and apply here analogously.
  • the substrate is stained in the color of the dyed micro sphere. Washing the substrate with buffer solution will remove excess dyed microsphere resulting in an essentially colorless substrate. Even though not visible to the naked eye, micro spheres will still be attached the substrate by preferably phys ical adsorption.
  • the solution with the dyed microsphere modified with the antibodies and/or aptamers can be applied locally to the substrate, e.g. by drip on, spray on or the like. This is in particular advanta geous if more than one antibody/aptamer system is applied to different discrete sections in the substrate.
  • the dyed microsphere modified with antibodies and/or aptamers are preferably obtained by a separate step.
  • Conventional dyed polystyrene microspheres can be obtained from Polyscience Inc. (USA).
  • Non-modified dyed microspheres can have a mean diameter of less than 6 mih, preferably less than 3 mih, even more prefera bly less than 1 mih and most preferably less than 500 nm.
  • the sphericity of the non-modified dyed microspheres is preferably > 0.9, more preferably > 0.93, most preferably > 0.96.
  • microspheres can be functionalized with carboxyl groups, but also hydroxyl- or amine groups are possible. Attachment of anti bodies and aptamers can be conducted by using carbodiimide cou pling techniques known in the art and previously described.
  • the substrate After attaching the modified dyed microspheres to the substrate, the substrate can be dried before use.
  • the capture antibody can be coupled to the substrate together with a protease, preferably a matrix metalloprotease. But also other proteases fulfilling the respective function are suitable.
  • the coupling can be obtained simultaneously with the antibodies/aptamers, preferably by using horseradish peroxidase (HRP), or in sequence.
  • HRP horseradish peroxidase
  • the method can provide the step of coupling two or more differ ent antibodies and/or aptamers each specific for another lung disease causing antigen to the substrate.
  • Antibodies and/or ap tamers for one specific antigen are preferably coupled in a dis crete section of the substrate. Coupling of capture antibodies and/or aptamers will preferably occur through chemical reaction such as carbodiimide crosslinking as previously described.
  • a fourth aspect of the invention relates to a method for produc ing a colorimetric mask as previously described.
  • the method com prises the step of providing a first layer with a colorimetric detection system obtainable by a method as previously described.
  • the first layer can be made from the same material as the sub strate.
  • the substrate can even be the first layer itself.
  • the first layer can also be made of material different from the sub strate.
  • the first layer can comprise a hydrophobic material that prevents the adsorption of aqueous body liquids such as salvia, sputum or nasal muscus.
  • the first layer can be polypropylene, hydrophobised material or any previously de scribed material.
  • the substrate can be attached to the first layer, for example by sewing, ticking or gluing.
  • the colorimetric detection system can be arranged in the centres of the first layer, meaning in the centre of the cloth forming the plane. Discrete sections of the colorimetric detections sys tem can be arranged cicular and in pie-shape. But also other lo cations and shapes are possible as long as a contact between capture antibody/aptamer and antigen is provided.
  • Another aspect of the invention refers to the use of dyed micro sphere modified with antibody and/or aptamer in a colorimetric detection system as previously described.
  • Figure 1 A detection system according to the invention.
  • Figure 2A A face mask according to the invention from the front side.
  • Figure 2B The mask of figure 2A from the opposite side in a perspective view.
  • Figure 3 Preparation method of the colorimetric detection system.
  • Figure 4 Working principle of the colorimetric detection system.
  • FIG. 1 shows a colorimetric detection system 1 according to the invention.
  • the colorimetric detection system 1 comprises a substrate 11, here in form of a strip.
  • the detection area 12 in form of a circle with dis crete detection sections A, B, C.
  • Each detection section A, B and C are able to detect another pathogen specific antigen.
  • section A can comprise influenza virus antibodies/ap- tamers coupled to blued-dyed microsphere.
  • Section B can comprise pneumonia antibodies/aptamer coupled to green dyed microsphere.
  • Section C can comprise Covid-19 antibodies/aptamer coupled to red dyed microsphere.
  • the detection sec tion A will change from colorless to blue while the other sec tions B and C remain colorless.
  • the detection section B will change from colorless to green while the other sections A and C remain colorless.
  • FIG. 1 shows the face mask 2 according to the invention from the front with the outer layer 21 and the fixation loops 22 on each side for fixation on the ears.
  • Figure 2B shows the mask 2 from the backside, meaning the side facing mouth and nose of the user.
  • the figure shows the first layer 23 comprising the detection area 12.
  • the first layer also forms the substrate of the colorimetric detection system.
  • the detection area 12 is provided as a circle in the centre of the mask 2, being the region clos est to mouth and nose when in use.
  • the detection area 12 is di vided into three different pie-shaped sections A, B, C. Each section will be coupled with another antibodies/aptamer system specific for one particular antigen thus providing the possibil ity of detecting three different pathogen specific antigen with one mask.
  • FIG 3 shows the modification of the substrate.
  • a cellulose substrate 31 is provided which is oxidized with sodium periodate (step a).
  • capture antibodies or aptamers or both are added to the oxidized cellulose and coupled by known carbodiimide coupling techniques to the cellulose (step b).
  • Step b can also comprise the step of coupling protease to the cellu lose using horseradish peroxidase (not shown).
  • Previously pre pared dyed microsphere modified with the antibodies/aptamers (detection antibodies) 32 are attached to the substrate by im mersing the cellulose substrate into a solution containing the dyed microspheres (step c).
  • the dyed microsphere are preferably obtained by reaction of colored polystyrene microspheres with free carboxyl groups with the respective antibodies and/or ap tamers by the previously mentioned carbodiimide coupling tech niques known in the art. Then, the substrate 31 is dried, attached to a first layer of a mask or being the first layer itself and mounted together with an outer layer 21 to the colorimetric mask 2 of figure 2.
  • Figure 4 shows the working principle of the colorimetric detec tion system.
  • the pathogen specific antigen 41 will be captured by the capture antibody/aptamer 42 (step d). If protease is pre sent the antigen 41 may be cleaved into smaller fragments (step e), thus allowing more detection antibodies 32 to be agglu tinated around the antigen 41 leading to a agglutinated network 43.
  • the network 43 comprises sufficient detection antibodies 32 to become visible to the naked eye. Movement of the detection antibodies 32 to the antigen's 41 reactive sites is preferably achieved through capillary effects upon humidification of the substrate.
  • MMP2 Matrix metalloproteinase-2
  • a pure cotton cellulose cloth was activated by immersing them in sodium periodate (Nal04) and of sulfuric acid (H2SO4) overnight at room tem ⁇ perature to obtained oxidized cellulose.
  • the oxidized cotton cellu lose was washed with PBS buffer, subsequently, with cold distilled water, to remove excess of oxidizing agent.
  • Periodate oxidation of cellulose cotton primarily activates hydroxyl groups into aldehyde or carboxyl groups, which will later be coupled with free amine groups of the anti bodies or aptamers.
  • hRSV Human respiratory syncytial virus
  • Ab Human respiratory syncytial virus
  • MMP2 protease were coated on the cotton cellulose to later support cleavage of the pathogen.
  • the activated cotton cellulose was in ⁇ cubated into a well-mixed solution of hRSV Ab and PBS and incubated overnight at 4 °C. Accordingly, MMP2 containing coupling buffer was used to couple MMP2 onto the cellulose similar as to the method described for the antibody. Horseredish peroxidase was used for facilitate coupling.
  • the cotton cellulose was washed to remove any unbounded antibody and MMP2 and thereafter 1% BSA was added to block the active sites of the cotton cellulose.
  • a control cotton cellulose cloth was incubated with 1% BSA solution in PBS buffer for 30 min at room temperature.
  • hRSV aptamer was washed with distilled water several times before being reacted with a coupling mixture of EDC/NHS overnight. Subse quently, the microspheres were washed with distilled water to re move excess coupling reagent. hRSV aptamer was thus linked to activated blue-dyed microspheres. Blocking of any unbound sites was achieved using 1% BSA solution in PBS for 30 min.
  • the modified cotton cellulose with the attached antibodies from step 3 were washed with PBS followed by immersion the cotton cel lulose into a solution of the modified microspheres of step 4, conjugated hRSV aptamer. Reaction was allowed to occur for a a couple of minutes. Subsequently, the cotton was washed with cold PBS to remove any unreacted microsphere. The cotton cellulose was dried and store at room temperature for 24 hrs.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Plasma & Fusion (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Textile Engineering (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to a colorimetric detection system for rapid detection of lung diseases. The detection system comprises antibodies and/or aptamers coupled to a substrate for capturing a lung disease specific antigen. The colorimetric system further comprises dyed microspheres modified with the antibodies and/or aptamers for visually detecting the lung disease specific antigen. The present invention also relates to a method of producing said detection system and a mask with such a detection system.

Description

Colorimetric detection system for rapid detection of infectious pulmonary diseases and a face mask with said colorimetric detec tion system
The present invention relates to a colorimetric detection system for rapid detection of lung diseases, a colorimetric mask com prising said detection system, a method for producing a colori metric detection system, a method for producing a mask compris ing said detections system and the use of dyed microsphere for a colorimetric detection system.
Pulmonary infections are global health problems that can be spread anywhere. Spreading is in particular a problem in regions where many people live in cramped conditions. Likewise, seasonal festivities, such as carnival, or religious events, such as pil grimages, pose a challenge in preventing the spread of diseases. Viral and bacterial microbes play a major role in lung infec tions and different attempts have been undertaken to prevent spreading of these microbes. One way to prevent spreading would be a rapid detection method and isolation of infected persons. Another relatively efficient way of preventing spreading is the use of facial mask that cover mouth and nose. If a patient with a lung disease is coughing or sneezing into the mask, viruses and microbes such as bacteria are caught in the layers of the mask preventing their uptake by another person standing close to the patient.
In addition to preventing the transmission of pathogens, it would also be desirable to be able to detect the symptom-causing disease as quickly and efficiently as possible. Indicator sys tems are known that are based on color changes. For example, Schaude et al (Sensors 2017, 17, p. 1365) describes indicator cotton swabs for a faster and less expensive way to obtain information about a wound status. The method is based on cotton swabs covalently functionalized with an indicator dye that changes color upon pH change visible to the naked eye. The pH can be used to determine the efficiency of wound healing. In case the pH is not optimal for wound healing, a distinct treat ment to change the wound pH can be applied.
However, this method is only limited to pH changes and difficult to apply to detection systems for determining an infection based on pathogens. Further, in some cases color changes has to be recorded using digital photography which is time consuming.
US 2019/0309357 A1 describes a detection system comprising a CRISPR system comprising an effector protein and one or more guide RNAs designed to bind to corresponding target molecules; an RNA masking construct and one or more detection aptamers cou pled with a detectable ligand. Enzymes generate a detectable signal by releasing the detectable ligand form the molecule which can be detected by e.g. fluorescence. The detection system can be prepared in freeze-dried format for convenient distribu tion and point-of-care. A comparable system has been applied to face mask (according to www.businessinsider.com). However, the system still needs hours to obtain a diagnostic signal. Further, the detection system is based on PCR techniques, which is rather expensive. Fluorescence measurements are susceptible to inter ference leading to noise signals thus complicating the analysis.
It is thus at least one objective of the present invention to overcome the drawbacks of the prior art. It is in particular an objective of the present invention to provide a colorimetric de tection system for rapid detection of lung diseases. It is an other objective of the present invention to provide a face mask with said colorimetric detection system that allows a rapid and reliable diagnosis of lung disease while, at the same time, pre venting the release of lung disease-causing pathogens into the environment.
The objectives are solved by the subject-matters of the inde pendent claims. Specific embodiments of the invention are de scribed in the dependent claims.
A first aspect of the invention relates to a colorimetric detec tion system for rapid detection of lung diseases. The detection system comprises antibodies and/or aptamers coupled to a sub strate for capturing a lung disease specific antigen. The color imetric system further comprises dyed microspheres modified with the antibodies and/or aptamers for visually detecting the lung disease specific antigen.
Antibodies are large Y-shaped proteins used by the immune system to identify pathogenic bacteria or viruses. The antibody recog nizes a unique molecule of the pathogen, called the antigen.
Aptamers are oligonucleotide or peptide molecules that bind to a specific target molecule. They can replace antibodies or used along antibodies for the same target.
The antibodies and/or aptamers coupled to the substrate are preferably coupled by covalent linkage and can be considered as capture antibodies and/or aptamers.
The modified dyed microspheres are preferably attached to the substrate by physical adsorption, thus being less strongly bound to the substrate than the capture antibodies/aptamers. However, they may also be bound by covalent linkage to the substrate. The antibodies and/or aptamers attached to the dyed microsphere are preferably of the same kind as the capture antibodies/aptamer but show at least the same antigen specificity as the capture antibodies/aptamers . During the description of the present in vention the antibodies attached to the dyed microsphere may be referred to as detection antibodies and/or detection aptamers.
With "dyed" every way of obtaining a colored microsphere is meant. For example "dyed" can refer to attached color-causing ligands; color pigments, compounds or dyes enclosed in the mi crosphere or with dye coated microspheres. Suitable dyes are for example Polybead® dyed microsphere obtainable by Polysciences Inc. The Polybeads may have different colors such as blue, green, yellow, red, pink, orange. The Polybead® microsphere can be Polybead® Polystyrene Microsphere, in the description also referred to as polystyrene microsphere or microsphere. The dyed microspheres can be provided as a particle suspension with a concentration of 2.5 % solid per 100 mL. The suspension may com prise particle diameters in the range of 0.05 mih to 90 mih. Parti cles with a diameter in the range of 0.5 to 90 mih account for 10 % or less of the solids in the suspension. The microspheres can be functionalized with carboxyl-, hydroxyl-, or amine groups for coupling of the antibodies and aptamers.
Preferably, the dyed microspheres used for coupling with the an tibodies and/or aptamers have a mean particle diameter of less than 6 mih, preferably even less than 3 mih, even more preferably less than 1 mih and most preferably less than 500 nm. The indi vidual microspheres in the colorimetric detection system can have different nominal particle diameter, but preferably do not exceed 6 mih. The sphericity of the dyed microspheres is prefera bly > 0.9, more preferably > 0.93, most preferably > 0.96. Individual microspheres with a diameter of less than 6 mih are not visible to the naked human eye and only allow detection upon agglutination thus providing a simple and effective detections system.
The substrate can comprise a protease, preferably a matrix-met alloproteinase. Preferably, the protease is coupled to the sub strate by functional groups such as carboxyl-, hydroxyl- or amine groups present on the substrate. Other proteases are also possible, for example PR3 or Elastase.
The protease has the advantage that a pathogen specific antigen coupled to the respective antibodies or aptamer are cleaved eas ier into smaller fragments (peptides and amino acids) thus al lowing more detection antibodies and/or aptamers to agglutinate to a larger network and thus allowing a faster detection.
The substrate can comprise discrete sections, each section being modified with antibodies and/or aptamers different from one of the other section for capturing a lung disease specific antigen different from the one captured in one of the other section.
Thus, a detection system is provided that allows the detection of different pathogens simultaneously. Preferred are two to four discrete sections, even more three sections. However, the detec tion system can comprise even more discrete sections, being only limited by the size of the substrate to allow visual detection.
For example, one discrete section may comprise antibodies and/or aptamers specific for a pneumonia inducing bacteria while the other discrete section comprises antibodies and/or aptamers spe cific for a flue inducing antigen. The dyed microsphere may have different colors in order to distinguish the different diseases. The antibodies and/or aptamers can be influenza virus antibodies and/or aptamers; or a pneumonia or pneumonia-inducing antibodies and/or aptamers.
In general, antigens that may be detectable by the colorimetric detection system are for example related to: viruses causing COVID-19, MERS, SARS, Flue A, Para Flue A Flue B, Para Flu B; bacteria such as Streptococcus, pneumonia, legionella, tubercu losis; or fungus such as actinomyces, aspergillus, Candida spp. The list is not to be understood as exhaustive as basically every disease can be detected of which specific antibodies/ap- tamers are available.
Preferably, the substrate is a solid support. The substrate can be a hydrophilic material and/or oxidized cellulose. The sub strate can be a cellulose based, paper-based or synthetic mate rial. For example, tissue paper, cotton or functionalized plas tic material can serve as substrate. The substrate can basically have any shape. Due to its easy handling the strip format is preferred. The substrate may have functional groups to allow coupling of the capture antibodies and/or aptamers, for example carboxyl-, hydroxyl- or amine groups, preferably by conventional carbodiimde coupling techniques. The carbodiimide technique is in particular used to couple proteins and peptides via their n- terminus to carboxylic groups to form stable conjugates. The hy- drophilicity allows the uptake of body liquids in the substrate. Basically, any hydrophilic substrate that provides the above- mentioned conditions can be used. Further examples are silica or metal hydroxide such as aluminium hydroxide.
Without being bound to theory, the working principle of the col orimetric system can be explained as follows: If a sample of salvia, sputum or nasal muscus of an infected person is applied to the substrate the substrate is humidified. The pathogen spe cific antigen is caught by the capture antibodies or aptamers covalently attached to the substrate. The protease allows cleav age of the antigen into smaller fragments for an efficient ag glutination of detection antibodies. The humidified substrate allows movement of the detection antibodies. The detection anti bodies or aptamers, preferably attached to the substrate by physical adsorption, will attach to the pathogen/antivirus and may form agglutinated network. The agglutination of the detec tion antibodies/aptamers causes an agglutination of the dyed mi crosphere resulting in the color appearance of the respective dyed microspheres to the naked eye and thus allowing visual de tection of the disease. Single dyed microsphere may be undetect able by the naked eye as described further above.
The colorimetric detection system provides a simple, efficient and fast way of detecting lung infections. The system can be easily prepared with low costs.
Preferably, the color appears within the first 30 min after ap plying the sample to the substrate, preferably between 1 and 10 min after application and even more preferably between 1 to 5 min after application and most preferably between 1 and 3 min after application.
Thus, the detection system does response faster than other known method such as fluorescent measurements and is less prone to er rors. Further, no additional equipment is used for detection al lowing its application everywhere.
A second aspect of the invention relates to a colorimetric face mask for rapid detection of lung diseases. The face mask is preferably designed to cover the mouth and the nose of a person. The face mask comprises a first layer comprising the colorimet ric detection system as previously described.
Advantageously, the first layer can be made from the same mate rial as the substrate. The substrate itself can serve as the first layer. The first layer can also be made of material dif ferent from the substrate. For example, the first layer can com prise a hydrophobic material that prevents the adsorption of aqueous body liquids such as salvia. The first layer can be pol ypropylene or a hydrophobised material. The first layer can be impregnated material. The substrate can be attached to the first layer, for example by sewing, ticking or gluing.
The face mask can comprise a second outer layer for protection against external pathogenic factors, preferably comprising a synthetic polymer such as polypropylene. The outer layer can be obtained by polymeric fibres for exampling by spinning or weav ing. Preferably, the outer layer is made of a hydrophobic mate rial to avoid the uptake of pathogen-containing fluids such as aerosols, salvia or mucus of persons standing nearby. The outer layer can comprise impregnated material. Most preferably, the outer layer is impermeable to microparticle but allows easy breathing of the user.
The impregnated material can be any textile or paper material, of natural or synthetic origin, that has been treated with res ins or other substances known in the art, or even has been guan idine-functionalized, in order to avoid water uptake and/or to obtain an antimicrobial effect.
The outer layer protects the user from being infected with a lung disease by others. At the same time is also prevents a false detection due to pathogens present in the environment instead of being present in the patient's body liquid. Further, it also avoids the visual detection by others which may lead to panic or the like.
With "pathogenic factors" all disease-causing pathogens, mi crobes and small particles are meant, in particular viruses, bacteria, fungus, dust and smog.
The working principle of the face mask can be explained similar as done with regard to the colorimetric detection system with the difference that the pathogen specific antigen containing sample is provided by sneezing or coughing into the mask. The coughing or snoozing brings the salvia, sputum or nasal muscus to the mask and humidifies the substrate. The humidified sub strate allows movement of detection antibodies to the antigen and the agglutination to the network allowing. The agglutination of the detection antibodies/aptamers causes an agglutination of the dyed microsphere resulting in the color appearance of the respective dyed microspheres to the naked eye and thus allowing visual detection of the disease. Single dyed microsphere may be undetectable by the naked eye as described further above.
The colorimetric mask offers a cheap, fast and reliable method of detection a patient's or any other infected person's lung disease and at the same time prevents the spreading of the path ogens, thus lessen the risk of disease spreading.
The color can appear within the first 30 min after release of the pathogen by e.g. sneezing or coughing, preferably between 1 and 10 min after release and even more preferably between 1 to 5 min after release and most preferably between 1 and 3 min. Preferably, the first layer comprises the colorimetric detection system with two or more discrete sections for the detection of different pathogens as previously described. For example, one discrete section may comprise antibodies and/or aptamers spe cific for a pneumonia inducing bacteria while the other discrete section comprises antibodies and/or aptamers specific for a flue inducing antigen. The dyed microsphere may have different colors in order to distinguish the different diseases.
Such a mask allows the detection of several lung diseases and thus no separate mask for each kind of infection has to be pro vided.
The colorimetric detection system can be located in the centre of the first layer, preferably in a circular arrangement. With "centre" is meant the middle of a plane forming cloth. Thus, the colorimetric detection system is closest to the mouth and nose, where the highest concentration on pathogen can be expected and thus leading to a fast detection. If more than one discrete sec tion is used, the detection system is preferably arranged in a circle and divided into pie-shaped sections. However, other shapes may also be possible as long as a contact between patho gen and detection system can be ensured.
The colorimetric mask can comprise a third inner layer for hid ing the result of the visually detected lung disease. The third inner layer is preferably permeable to fluids and preferably comprises a cotton based material. Permeability can thus either be achieved by the material itself or by providing fluid pas sage, such as holes, in the third layer to allow contact of the pathogen containing body fluid with the detection system in the first layer. In principle, all material mentioned with regard to the first and second layer can be used for the third layer. The third layer avoids the visual detection of the disease by the patient himself. Most preferred, the visual appearance of the colors can only be interpreted by medical staff and thus avoiding revelation to the patient or surrounding people which may cause panic or fear.
The mask may comprise fixation loops for fixing the mask to the head. The loops can be handcrafted rubber strings with two metal copper rings inside, rubber bands or cords for closing at the back of the head. This way, the mask is holed in place and wear ing is comfortable. The mask can thus be worn for a couple of hours.
A third aspect of the invention refers to a method for producing a colorimetric system as previously described. The method com prises the steps of
Providing a substrate with reactive sites towards antibodies and/or aptamer, coupling of antibodies and/or aptamers specific for a lung disease causing antigen to the reactive sites, blocking of non-reacted active sites, attaching dyed microspheres modified with the antibodies and/or aptamers to the substrate, preferably by immersing the substrate into a solution comprising the modified dyed microspheres.
The substrate may be a hydrophilic material already containing the reactive sites or the substrate may have been modified in a previous step. The substrate can originate from cellulose which has been oxidized. The substrate can be oxidized cellulose. The substrate can be any other hydrophilic material that provides reactive sites towards antibodies and/or aptamers. The antibodies and/or aptamers may be coupled to the substrate via the reactive groups. The reactive groups can be carboxyl-, hydroxyl-, amine- or sulfuric groups. Carboxyl groups are pre ferred. Coupling of the antibodies and aptamers can be conducted by carbodiimide crosslinking chemistry known in the art. In gen eral, any coupling method that allows the N- or C-terminus of the antibody/aptamer to be coupled to the substrate is possible.
Blocking of non-reactive sites is preferably obtained by using bovine serum albumin (BSA).
Attachment of the dyed microspheres modified with the antibodies and/or aptamers to the substrate is preferably obtained by phys ical adsorption. Most preferably, the substrate can be immersed into a solution comprising the modified dyed microspheres. De tails to the microsphere have been previously provided and apply here analogously. After immersing the substrate into the solu tion, the substrate is stained in the color of the dyed micro sphere. Washing the substrate with buffer solution will remove excess dyed microsphere resulting in an essentially colorless substrate. Even though not visible to the naked eye, micro spheres will still be attached the substrate by preferably phys ical adsorption.
Other methods then immersing are also possible. For example, the solution with the dyed microsphere modified with the antibodies and/or aptamers can be applied locally to the substrate, e.g. by drip on, spray on or the like. This is in particular advanta geous if more than one antibody/aptamer system is applied to different discrete sections in the substrate.
The dyed microsphere modified with antibodies and/or aptamers are preferably obtained by a separate step. Conventional dyed polystyrene microspheres can be obtained from Polyscience Inc. (USA). Non-modified dyed microspheres can have a mean diameter of less than 6 mih, preferably less than 3 mih, even more prefera bly less than 1 mih and most preferably less than 500 nm. The sphericity of the non-modified dyed microspheres is preferably > 0.9, more preferably > 0.93, most preferably > 0.96.
The microspheres can be functionalized with carboxyl groups, but also hydroxyl- or amine groups are possible. Attachment of anti bodies and aptamers can be conducted by using carbodiimide cou pling techniques known in the art and previously described.
After attaching the modified dyed microspheres to the substrate, the substrate can be dried before use.
Preferably, the capture antibody can be coupled to the substrate together with a protease, preferably a matrix metalloprotease. But also other proteases fulfilling the respective function are suitable. The coupling can be obtained simultaneously with the antibodies/aptamers, preferably by using horseradish peroxidase (HRP), or in sequence.
The method can provide the step of coupling two or more differ ent antibodies and/or aptamers each specific for another lung disease causing antigen to the substrate. Antibodies and/or ap tamers for one specific antigen are preferably coupled in a dis crete section of the substrate. Coupling of capture antibodies and/or aptamers will preferably occur through chemical reaction such as carbodiimide crosslinking as previously described.
A fourth aspect of the invention relates to a method for produc ing a colorimetric mask as previously described. The method com prises the step of providing a first layer with a colorimetric detection system obtainable by a method as previously described. The first layer can be made from the same material as the sub strate. The substrate can even be the first layer itself. The first layer can also be made of material different from the sub strate. For example, the first layer can comprise a hydrophobic material that prevents the adsorption of aqueous body liquids such as salvia, sputum or nasal muscus. The first layer can be polypropylene, hydrophobised material or any previously de scribed material. The substrate can be attached to the first layer, for example by sewing, ticking or gluing.
The colorimetric detection system can be arranged in the centres of the first layer, meaning in the centre of the cloth forming the plane. Discrete sections of the colorimetric detections sys tem can be arranged cicular and in pie-shape. But also other lo cations and shapes are possible as long as a contact between capture antibody/aptamer and antigen is provided.
Another aspect of the invention refers to the use of dyed micro sphere modified with antibody and/or aptamer in a colorimetric detection system as previously described.
The invention will be described in more details with regard to the following figures and examples. The invention is not limited to these specific embodiments.
It shows:
Figure 1: A detection system according to the invention.
Figure 2A: A face mask according to the invention from the front side.
Figure 2B: The mask of figure 2A from the opposite side in a perspective view. Figure 3: Preparation method of the colorimetric detection system.
Figure 4: Working principle of the colorimetric detection system.
Figure 1 shows a colorimetric detection system 1 according to the invention. The colorimetric detection system 1 comprises a substrate 11, here in form of a strip. In the centre of the strip 11 is the detection area 12 in form of a circle with dis crete detection sections A, B, C. Each detection section A, B and C are able to detect another pathogen specific antigen. For example, section A can comprise influenza virus antibodies/ap- tamers coupled to blued-dyed microsphere. Section B can comprise pneumonia antibodies/aptamer coupled to green dyed microsphere. Section C can comprise Covid-19 antibodies/aptamer coupled to red dyed microsphere.
If a patient's sample is applied to the detection system 1 and the patient is infected with influenza virus, the detection sec tion A will change from colorless to blue while the other sec tions B and C remain colorless.
If a patient's sample is applied to the detection system 1 and the patient is infected with pneumonia, the detection section B will change from colorless to green while the other sections A and C remain colorless.
If a patient's sample is applied to the detection system 1 and the patient is infected with Covid 19, the detection section C will change from colorless to red while the other sections A and B remain colorless. Figure 2A shows the face mask 2 according to the invention from the front with the outer layer 21 and the fixation loops 22 on each side for fixation on the ears.
Figure 2B shows the mask 2 from the backside, meaning the side facing mouth and nose of the user. The figure shows the first layer 23 comprising the detection area 12. Thus, in this spe cific example, the first layer also forms the substrate of the colorimetric detection system. The detection area 12 is provided as a circle in the centre of the mask 2, being the region clos est to mouth and nose when in use. The detection area 12 is di vided into three different pie-shaped sections A, B, C. Each section will be coupled with another antibodies/aptamer system specific for one particular antigen thus providing the possibil ity of detecting three different pathogen specific antigen with one mask.
Figure 3 shows the modification of the substrate. Firstly, a cellulose substrate 31 is provided which is oxidized with sodium periodate (step a). Secondly, capture antibodies or aptamers or both are added to the oxidized cellulose and coupled by known carbodiimide coupling techniques to the cellulose (step b). Step b can also comprise the step of coupling protease to the cellu lose using horseradish peroxidase (not shown). Previously pre pared dyed microsphere modified with the antibodies/aptamers (detection antibodies) 32 are attached to the substrate by im mersing the cellulose substrate into a solution containing the dyed microspheres (step c). The dyed microsphere are preferably obtained by reaction of colored polystyrene microspheres with free carboxyl groups with the respective antibodies and/or ap tamers by the previously mentioned carbodiimide coupling tech niques known in the art. Then, the substrate 31 is dried, attached to a first layer of a mask or being the first layer itself and mounted together with an outer layer 21 to the colorimetric mask 2 of figure 2.
Figure 4 shows the working principle of the colorimetric detec tion system. When salvia or nasal muscus sample is applied to the substrate, the pathogen specific antigen 41 will be captured by the capture antibody/aptamer 42 (step d). If protease is pre sent the antigen 41 may be cleaved into smaller fragments (step e), thus allowing more detection antibodies 32 to be agglu tinated around the antigen 41 leading to a agglutinated network 43. The network 43 comprises sufficient detection antibodies 32 to become visible to the naked eye. Movement of the detection antibodies 32 to the antigen's 41 reactive sites is preferably achieved through capillary effects upon humidification of the substrate.
EXAMPLE
1. Reagents
Matrix metalloproteinase-2 (MMP2) was synthesized by Pepmic Co. (Suzhou, Jiangsu, China).
Sodium phosphate and monopotassium phosphate, Tris-Base, Sodium acetate; bovine serum albumin (BSA), sodium chloride, phosphate buffered saline (PBS), ethyl-3- (3-dimethylaminopropyl)-car- bodiimide (EDC), N-hydroxysuccinimide (NHS), ethylenediaminetet- raacetic acid (EDTA) phosphate buffered were all purchased from Sigma-Aldrich (Darmstadt, Germany). Carboxylic acid functionalized microspheres of different colors (orange and blue) were obtained from Polysciences Inc. (Polysciences Inc., Warrington, PA).
All Aptameres of pathogen were provided from Aptamer Sciences (Ap- tamer Sciences Inc, Korea). All antibody and antigen for testing the system were provided from abeam (abeam, UK), Sodium peroxide/fhSCg were purchased from Sigma- Aldrich (Darmstadt, Germany). Pure cotton cellulose were obtained from Filmar (Egypt).
2.Activation of cotton cellulose serving as substrate
A pure cotton cellulose cloth was activated by immersing them in sodium periodate (Nal04) and of sulfuric acid (H2SO4) overnight at room tem¬ perature to obtained oxidized cellulose. The oxidized cotton cellu lose was washed with PBS buffer, subsequently, with cold distilled water, to remove excess of oxidizing agent. Periodate oxidation of cellulose cotton primarily activates hydroxyl groups into aldehyde or carboxyl groups, which will later be coupled with free amine groups of the anti bodies or aptamers.
3.Immobilization of protease/antibody on the activated cotton
Human respiratory syncytial virus (hRSV) antibody (Ab) and MMP2 protease were coated on the cotton cellulose to later support cleavage of the pathogen. The activated cotton cellulose was in¬ cubated into a well-mixed solution of hRSV Ab and PBS and incubated overnight at 4 °C. Accordingly, MMP2 containing coupling buffer was used to couple MMP2 onto the cellulose similar as to the method described for the antibody. Horseredish peroxidase was used for facilitate coupling. The cotton cellulose was washed to remove any unbounded antibody and MMP2 and thereafter 1% BSA was added to block the active sites of the cotton cellulose. A control cotton cellulose cloth was incubated with 1% BSA solution in PBS buffer for 30 min at room temperature.
4.Conjugation of Aptamer to blue polymeric microsphere
Blue dyed microsphere with diameter in the range of 300 nm were used. The microsphere contained attached carboxyl groups. hRSV aptamer was washed with distilled water several times before being reacted with a coupling mixture of EDC/NHS overnight. Subse quently, the microspheres were washed with distilled water to re move excess coupling reagent. hRSV aptamer was thus linked to activated blue-dyed microspheres. Blocking of any unbound sites was achieved using 1% BSA solution in PBS for 30 min.
5.Attachment of microsphere to the cotton cellulose
The modified cotton cellulose with the attached antibodies from step 3 were washed with PBS followed by immersion the cotton cel lulose into a solution of the modified microspheres of step 4, conjugated hRSV aptamer. Reaction was allowed to occur for a a couple of minutes. Subsequently, the cotton was washed with cold PBS to remove any unreacted microsphere. The cotton cellulose was dried and store at room temperature for 24 hrs.
6.The assay technique for control After 24 hrs, the cellulose cotton with the associated microspheres and capture antibodies were exposed to a sample of a patient's salvia, infected with respiratory syncytial virus. A blue color appeared within 3 min, visually displaying the infection.

Claims

Claims
1. Colorimetric detection system for rapid detection of lung diseases comprising antibodies and/or aptamers coupled to a substrate for capturing a lung disease specific antigen, characterized in that the colorimetric system further com prises dyed microspheres modified with the antibodies and/or aptamers for visually detecting the lung disease specific antigen.
2. Colorimetric detection system according to claim 1 wherein the dyed microspheres have a mean diameter of less than 6 mih, preferably less than 3 mih, even more preferably less than 1 mih and most preferably less than 500 nm.
3. Colorimetric detection system according to one of the pre vious claims, wherein the substrate comprises a protease, preferably a matrix-metalloproteinase.
4. Colorimetric detection system according to one of the pre vious claims, wherein the substrate comprises discrete sec tions, each section being modified with antibodies and/or aptamers different from one of the other section for cap turing a lung disease specific antigen different from the one captured in one of the other section.
5. Colorimetric detection system according to one of the pre vious claims, wherein the antibodies and/or aptamers are influenza virus antibodies and/or aptamers; or a pneumonia or pneumonia-inducing antibodies and/or aptamers.
6. Colorimetric detection system according to one of the pre vious claims, wherein the substrate is a hydrophilic mate rial and/or oxidized cellulose.
7. A colorimetric face mask comprising a first layer with a colorimetric detection system according to claim 1 to 6.
8. The colorimetric face mask according to claim 7 comprising a second outer layer, preferably comprising a synthetic polymer, most preferably polypropylene.
9. The colorimetric face mask according to one of claims 7 or 8, wherein the colorimetric detection system is located in the centre of the first layer, preferably in a circular ar rangement.
10. The colorimetric mask according to one of claims 7 to 9 comprising a third inner layer for hiding the result of the visually detected lung disease.
11. The colorimetric mask according to claim 10, wherein the third inner layer is permeable to fluids and preferably comprises a cotton based material.
12. The colorimetric mask according to one of claims 7 to 11, wherein the mask comprises fixation loops.
13. Method for producing a colorimetric detection system ac cording to one of claims 1 to 6, the method comprising the steps of
- Providing a substrate with reactive sites towards anti bodies and/or aptamer,
- coupling of antibodies and/or aptamers specific for a lung disease causing antigen to the reactive sites,
- blocking of non-reacted active sites,
- attaching dyed microspheres modified with the antibodies and/or aptamers to the substrate, preferably by immersing the substrate into a solution comprising the modified dyed microspheres.
14. Method according to claim 13, wherein a protease, prefera bly a matrix metalloproteinase, is coupled to the sub strate.
15. Method according to claim 13 or 14, wherein two or more different antibodies and/or aptamers each specific for an other lung disease causing antigen are coupled to the sub strate.
16. Method according to one of claims 13 to 15, wherein the substrate is a hydrophilic material and/or oxidized cellu lose.
17. Method according to one of claims 13 to 16, wherein the non-modified dyed microspheres have a diameter less than 6 mih, preferably less than 3 mih, even more preferably less than 1 mih and most preferably less than 500 nm.
18. Method for producing a mask according to one of claims 7 to 12 comprising the steps:
- Providing a first layer with a colorimetric detection system obtainable by a method according to one of the claims 13 to 17.
19. Method according to claim 18, wherein a second outer layer is provided, preferably an outer layer comprising a syn thetic polymer.
20. Use of dyed microsphere modified with antibody and/or ap- tamer in a colorimetric detection system according to one of claims 1 to 6.
PCT/IB2021/051658 2020-02-29 2021-02-27 Colorimetric detection system for rapid detection of infectious pulmonary diseases and a face mask with said colorimetric detection system Ceased WO2021171268A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US17/802,408 US20230184757A1 (en) 2020-02-29 2021-02-27 Colorimetric detection system for rapid detection of infectious pulmonary diseases and a face mask with said colorimetric detection system
EP21714665.3A EP4111199B1 (en) 2020-02-29 2021-02-27 Colorimetric detection system for rapid detection of infectious pulmonary diseases and a face mask with said colorimetric detection system
CN202180017082.9A CN115210570A (en) 2020-02-29 2021-02-27 Colorimetric detection system for rapid detection of infectious pulmonary diseases and mask having the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062983620P 2020-02-29 2020-02-29
US62/983,620 2020-02-29

Publications (1)

Publication Number Publication Date
WO2021171268A1 true WO2021171268A1 (en) 2021-09-02

Family

ID=75252586

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2021/051658 Ceased WO2021171268A1 (en) 2020-02-29 2021-02-27 Colorimetric detection system for rapid detection of infectious pulmonary diseases and a face mask with said colorimetric detection system

Country Status (4)

Country Link
US (1) US20230184757A1 (en)
EP (1) EP4111199B1 (en)
CN (1) CN115210570A (en)
WO (1) WO2021171268A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220213564A1 (en) * 2020-03-12 2022-07-07 New England Biolabs, Inc. Rapid Diagnostic Test for LAMP
KR20230075839A (en) * 2021-11-23 2023-05-31 동의과학대학교산학협력단 Coronavirus Diagnosis Masks
US11732315B2 (en) 2020-03-12 2023-08-22 New England Biolabs, Inc. Rapid diagnostic test for lamp
WO2023187480A1 (en) * 2022-03-30 2023-10-05 Hasan Bagheri Colorimetric system for detection of covid-19 using exhaled breath metabolites

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025005304A1 (en) * 2023-06-30 2025-01-02 株式会社デジタルストリーム Detection member for object to be detected and method for detecting object to be detected using same

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998029727A2 (en) * 1996-12-31 1998-07-09 Stephon, Robert, L. Microsphere-enhanced immunoassay for the detection of veterinary diseases
WO2009126336A1 (en) * 2008-04-11 2009-10-15 Becton, Dickinson And Company Methods of controlling the sensitivity and dynamic range of a homogeneous assay
US20100092944A1 (en) * 2005-07-01 2010-04-15 Arbor Vita Corporation Detection of influenza virus
KR20170063000A (en) * 2015-11-30 2017-06-08 고려대학교 산학협력단 Method of Detecting Virus Using Virus Specific Nucleic Acid Aptamer-Nanoparticle Complex
US20190309357A1 (en) 2016-12-09 2019-10-10 The Broad Institute, Inc. Crispr effector system based diagnostics

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2104451A4 (en) * 2006-01-25 2010-01-06 Pipex Inc Droplet collection devices and methods to detect and control airborne communicable diseases utilizing rfid
CN110540600B (en) * 2018-12-20 2021-01-29 湖北工业大学 Preparation method of latex microsphere immunochromatographic test paper based on Klebsiella pneumoniae surface protein

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998029727A2 (en) * 1996-12-31 1998-07-09 Stephon, Robert, L. Microsphere-enhanced immunoassay for the detection of veterinary diseases
US20100092944A1 (en) * 2005-07-01 2010-04-15 Arbor Vita Corporation Detection of influenza virus
WO2009126336A1 (en) * 2008-04-11 2009-10-15 Becton, Dickinson And Company Methods of controlling the sensitivity and dynamic range of a homogeneous assay
KR20170063000A (en) * 2015-11-30 2017-06-08 고려대학교 산학협력단 Method of Detecting Virus Using Virus Specific Nucleic Acid Aptamer-Nanoparticle Complex
US20190309357A1 (en) 2016-12-09 2019-10-10 The Broad Institute, Inc. Crispr effector system based diagnostics

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHUA MING HUI ET AL: "Face Masks in the New COVID-19 Normal: Materials, Testing, and Perspectives", RESEARCH, vol. 2020, 7 August 2020 (2020-08-07), pages 1 - 40, XP055787873, Retrieved from the Internet <URL:http://downloads.spj.sciencemag.org/research/2020/7286735.xml> DOI: 10.34133/2020/7286735 *
SCHAUDE ET AL., SENSORS, vol. 17, 2017, pages 1365

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220213564A1 (en) * 2020-03-12 2022-07-07 New England Biolabs, Inc. Rapid Diagnostic Test for LAMP
US11525166B2 (en) * 2020-03-12 2022-12-13 New England Biolabs, Inc. Rapid diagnostic test for LAMP
US11732315B2 (en) 2020-03-12 2023-08-22 New England Biolabs, Inc. Rapid diagnostic test for lamp
KR20230075839A (en) * 2021-11-23 2023-05-31 동의과학대학교산학협력단 Coronavirus Diagnosis Masks
KR102704892B1 (en) * 2021-11-23 2024-09-09 동의과학대학교 산학협력단 Coronavirus Diagnosis Masks
WO2023187480A1 (en) * 2022-03-30 2023-10-05 Hasan Bagheri Colorimetric system for detection of covid-19 using exhaled breath metabolites

Also Published As

Publication number Publication date
CN115210570A (en) 2022-10-18
US20230184757A1 (en) 2023-06-15
EP4111199A1 (en) 2023-01-04
EP4111199C0 (en) 2025-06-25
EP4111199B1 (en) 2025-06-25

Similar Documents

Publication Publication Date Title
EP4111199B1 (en) Colorimetric detection system for rapid detection of infectious pulmonary diseases and a face mask with said colorimetric detection system
CN105424931B (en) Helicobacter Pylori urease antibody IgM, IgG associating device for fast detecting and preparation method thereof
CN102253193A (en) Magnetic fluorescent kit for rapidly detecting microbes as well as preparation method and use method thereof
KR20120010222A (en) High Pathogenic Avian Influenza H5N1 Subtype Virus Detection Kit
CA2513579A1 (en) Immunoassay and method of use
CN103558381A (en) Immunochromatographic test paper for detecting human immunodeficiency virus antibodies and preparation method thereof
CN105478087A (en) Method for preparing carboxyl magnetic beads based on glucan coating and application of method
CN115015543B (en) Multi-pathogen joint detection device and preparation method thereof
CN101661040A (en) Spittle rapid detection strip for treponema pallidum antibody
CN114324879B (en) Novel qualitative detection kit for coronavirus neutralizing antibody based on colloidal gold double-antibody sandwich method
CN101253261A (en) Diagnostic Test Kits
KR102568245B1 (en) Immunochromatography device having reduced background noises, and method for reducing background noises in immunochromatographty device
JP6656052B2 (en) Immunoassay method, immunoassay kit and lateral flow type chromatographic test strip
CN101614740B (en) Hepatitis A virus antigen saliva fast detection test paper strip
CN209690322U (en) A kind of chlamydia pneumoniae (cp) Test paper box
CN101661037A (en) Spittle rapid detection strip for chlamydia trachomatis antibody
CN103235131A (en) Lateral flow immunochromatographic determination product for detecting yellow fever viruses and preparation method of lateral flow immunochromatographic determination product
CN105137060A (en) Immune color silica microsphere preparation method, color test paper, and color test paper preparation method
CN101614743A (en) Hepatitis B virus surface antigen saliva fast detection test paper strip
CN110501493A (en) A kind of detection kit of hemadsorption virus type 1&#39;s IgM antibody
CN102445536A (en) Gold-labeled immune test strip for detecting equine encephalitis virus antibody and preparation method and application thereof
CN101661039A (en) Gonorrhea-antigen spittle rapid detection strip
CN114414816A (en) Mycotoxin detection probe and kit, and mycotoxin detection method
CN1725012A (en) Detection method of poultry influenze virus antigen and its golden label fast diagnosis reagent box and preparation method
US8642275B2 (en) Immunological tests for the presence of bacteria which make use of antibodies obtained using a specific method

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21714665

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2021714665

Country of ref document: EP

Effective date: 20220929

NENP Non-entry into the national phase

Ref country code: DE

WWG Wipo information: grant in national office

Ref document number: 2021714665

Country of ref document: EP